JP2011506591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506591A5 JP2011506591A5 JP2010538900A JP2010538900A JP2011506591A5 JP 2011506591 A5 JP2011506591 A5 JP 2011506591A5 JP 2010538900 A JP2010538900 A JP 2010538900A JP 2010538900 A JP2010538900 A JP 2010538900A JP 2011506591 A5 JP2011506591 A5 JP 2011506591A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- piperazino
- compound according
- alkyl
- saturated aliphatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- -1 pyrrolidino, piperidino, piperazino, morpholino Chemical group 0.000 claims 35
- 125000001931 aliphatic group Chemical group 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 12
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CIN*c1ccnc2nc(*)c(*)nc12 Chemical compound CIN*c1ccnc2nc(*)c(*)nc12 0.000 description 1
- GUMBTPYGNZMDCU-UHFFFAOYSA-N Cc1cc(SC)c(C)cc1 Chemical compound Cc1cc(SC)c(C)cc1 GUMBTPYGNZMDCU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1501907P | 2007-12-19 | 2007-12-19 | |
| US61/015,019 | 2007-12-19 | ||
| PCT/GB2008/004208 WO2009077766A1 (en) | 2007-12-19 | 2008-12-19 | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011506591A JP2011506591A (ja) | 2011-03-03 |
| JP2011506591A5 true JP2011506591A5 (enExample) | 2012-01-12 |
| JP5511680B2 JP5511680B2 (ja) | 2014-06-04 |
Family
ID=40342728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538900A Active JP5511680B2 (ja) | 2007-12-19 | 2008-12-19 | ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US8198279B2 (enExample) |
| EP (1) | EP2229391B1 (enExample) |
| JP (1) | JP5511680B2 (enExample) |
| KR (1) | KR101665143B1 (enExample) |
| CN (1) | CN101945869B (enExample) |
| AU (1) | AU2008337286B2 (enExample) |
| BR (1) | BRPI0821227A2 (enExample) |
| CA (1) | CA2709257C (enExample) |
| DK (1) | DK2229391T3 (enExample) |
| EA (1) | EA019974B1 (enExample) |
| ES (1) | ES2520940T3 (enExample) |
| IL (1) | IL206330A (enExample) |
| MX (1) | MX2010006739A (enExample) |
| NZ (1) | NZ586418A (enExample) |
| PL (1) | PL2229391T3 (enExample) |
| UA (1) | UA105763C2 (enExample) |
| WO (1) | WO2009077766A1 (enExample) |
| ZA (1) | ZA201004524B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2229391B1 (en) | 2007-12-19 | 2014-08-06 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| CA2786834C (en) | 2010-02-01 | 2018-10-16 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| WO2011124930A1 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | P38 map kinase inhibitors |
| US8933228B2 (en) * | 2010-06-17 | 2015-01-13 | Respivert, Ltd. | Respiratory formulations and compounds for use therein |
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| JP6322413B2 (ja) | 2011-03-10 | 2018-05-09 | プロヴェクタス ファーマテック，インク． | 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ |
| EP2508184A1 (en) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Pyridopyrazine derivatives and their use |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| EP2747767B8 (en) | 2011-08-26 | 2019-07-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN108794411B (zh) | 2011-09-14 | 2022-06-07 | 润新生物公司 | 某些化学实体、组合物及方法 |
| CN103130686B (zh) * | 2011-12-02 | 2016-09-14 | 天津市国际生物医药联合研究院 | N，n′-不对称二芳基取代脲类化合物及其制备方法和用途 |
| US9670180B2 (en) | 2012-01-25 | 2017-06-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| HUE045353T2 (hu) | 2012-04-13 | 2019-12-30 | Epizyme Inc | N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)-metil)-5-(etil-(tetrahidro-2H-pirán-4-il) -amino)-4-metil-4'-(morfolino-metil)-[1,1'-bifenil]-3-karboxamid-hidrobromid a hematológiai rendszer egy sejtszaporodásos rendellenességének kezelésében való alkalmazásra |
| CN104812389B (zh) | 2012-09-24 | 2020-07-17 | 润新生物公司 | 某些化学实体、组合物及方法 |
| UA115451C2 (uk) | 2012-10-02 | 2017-11-10 | Байєр Кропсайєнс Акцієнгезелльшафт | Гетероциклічні сполуки як пестициди |
| CA2887562C (en) | 2012-10-15 | 2021-01-12 | Epizyme, Inc. | Substituted benzene compounds |
| EP2916838B1 (en) | 2012-11-12 | 2019-03-13 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| SG11201602269QA (en) | 2013-10-16 | 2016-04-28 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
| GB201320729D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| JP7523886B2 (ja) | 2016-02-23 | 2024-07-29 | キャンサー・リサーチ・テクノロジー・リミテッド | 少なくとも２つの非必須アミノ酸を欠くダイエタリー製品 |
| US20200281243A1 (en) | 2017-11-13 | 2020-09-10 | Cancer Research Technology Ltd | Dietary product |
| GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| GB201818649D0 (en) | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
| GB201818651D0 (en) | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
| GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| US20230089368A1 (en) | 2019-07-19 | 2023-03-23 | Anagenesis Biotechnologies S.A.S. | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
| CN114391009A (zh) | 2019-08-08 | 2022-04-22 | Bci制药公司 | 作为蛋白激酶抑制剂的喹啉衍生物 |
| CA3166630A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
| CA3181158A1 (en) | 2020-06-03 | 2021-12-09 | Oliver D. K. MADDOCKS | Formulations for personalized methods of treatment |
| US12109184B2 (en) | 2020-06-04 | 2024-10-08 | Faeth Therapeutics, Inc. | Personalized methods of treating cancer |
| US20230219934A1 (en) * | 2020-06-24 | 2023-07-13 | Purdue Research Foundation | 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors |
| CN112480109B (zh) * | 2020-11-16 | 2022-04-01 | 浙江大学 | 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途 |
| EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
| CN114105876A (zh) * | 2021-12-08 | 2022-03-01 | 沈阳科创化学品有限公司 | 一种制备乙唑螨腈中间体的方法 |
| GB202208347D0 (en) | 2022-06-07 | 2022-07-20 | Univ Court Univ Of Glasgow | Targets for cancer therapy |
| GB202209622D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Compounds |
| GB202209624D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Prodrugs |
| JP2025539843A (ja) | 2022-11-24 | 2025-12-09 | ビー．シー．アイ．ファーマ | プロテインキナーゼ阻害剤としてのピリジン誘導体 |
| CN115884487B (zh) * | 2023-02-16 | 2023-05-26 | 浙大城市学院 | 基于针式协同双螺旋电极介质阻挡放电管 |
| TW202448857A (zh) * | 2023-05-12 | 2024-12-16 | 大陸商正大天晴藥業集團股份有限公司 | 含有芳香二並環的化合物 |
| WO2025021943A1 (en) | 2023-07-26 | 2025-01-30 | Neuralis | Quinazolinone, benzoxazinone and benzoxazepinone derivatives as protein kinase inhibitors |
| WO2025229029A1 (en) | 2024-04-30 | 2025-11-06 | Gorgoulis Vassilis G | Conjugate of a senotherapeutic moiety and a lipid-targeting moiety |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082845A (en) | 1977-04-25 | 1978-04-04 | Merck & Co., Inc. | 3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines |
| JPS5665863A (en) | 1979-10-31 | 1981-06-03 | Tokyo Organ Chem Ind Ltd | Novel aniline derivative, its preparation and pesticide containing the same |
| JPS5738777A (en) | 1980-08-19 | 1982-03-03 | Sogo Yatsukou Kk | 2-sufanilamidopyrathyn derivative |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| US5879672A (en) | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| WO1996009381A1 (en) | 1994-09-22 | 1996-03-28 | Helsinki University Licensing Ltd. Oy | Promoter for the receptor tyrosine kinase, tie |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| JP4009681B2 (ja) * | 1995-11-07 | 2007-11-21 | キリンファーマ株式会社 | 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物 |
| ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| CA2263479A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Quinoline derivatives inhibiting the effect of growth factors such as vegf |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| CA2305370C (en) | 1997-09-26 | 2006-11-28 | Gerald Mcmahon | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| CA2315646C (en) * | 1997-12-22 | 2010-02-09 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| US20010053946A1 (en) * | 1998-09-04 | 2001-12-20 | R. R. Donnelley & Sons Company | System for controlling feeders of a package assembly apparatus |
| CA2346448A1 (en) | 1998-12-16 | 2000-06-22 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| JP2002534380A (ja) | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による喘息の治療 |
| NZ513006A (en) * | 1999-01-22 | 2003-10-31 | Kirin Brewery | Quinoline derivatives and quinazoline derivatives |
| WO2000045435A1 (en) | 1999-01-29 | 2000-08-03 | The University Of Akron | Polyimides used as microelectronic coatings |
| CN1373660A (zh) | 1999-07-16 | 2002-10-09 | 沃尼尔·朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| RU2002110461A (ru) * | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
| GB2356398A (en) | 1999-11-18 | 2001-05-23 | Lilly Dev Ct S A | Preparation of arylsulfamides |
| US6610688B2 (en) | 1999-12-21 | 2003-08-26 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| JP2004517080A (ja) | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体 |
| KR20020096367A (ko) | 2001-06-19 | 2002-12-31 | 주식회사 티지 바이오텍 | 관절염 예방 또는 치료제 및 그것의 스크리닝 방법 |
| JP4643909B2 (ja) | 2001-12-21 | 2011-03-02 | ザ ウェルカム トラスト リミテッド | 遺伝子 |
| US20030180226A1 (en) | 2002-01-23 | 2003-09-25 | Haughton Pauline A. | Anti-bacterial sneeze spray |
| EP1534268A4 (en) | 2002-08-09 | 2006-11-02 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
| WO2004083458A1 (en) | 2003-03-20 | 2004-09-30 | Universite Catholique De Louvain | Medical use of ras antagonists for the treatment of capillary malformation |
| WO2004110452A1 (en) | 2003-06-13 | 2004-12-23 | Novartis Ag | 2-aminopyrimidine derivatives as raf kinase inhibitors |
| CA2556160A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists |
| TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
| TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| AU2005278959A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as B-Raf inhibitors |
| CA2583096A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Quinoxalines as b raf inhibitors |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| GB0428082D0 (en) * | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| US20070078121A1 (en) | 2004-12-23 | 2007-04-05 | Flynn Daniel L | Enzyme modulators and treatments |
| WO2007059202A2 (en) | 2005-11-15 | 2007-05-24 | Bayer Healthcare Ag | Pyrazolyl urea derivatives useful in the treatment of cancer |
| MX2008006979A (es) | 2005-12-01 | 2009-01-14 | Bayer Healthcare Llc | Compuestos de urea utiles en el tratamiento contra el cancer. |
| EP1957460A1 (en) | 2005-12-08 | 2008-08-20 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| CN101040720A (zh) | 2006-03-24 | 2007-09-26 | 沈华立 | 一种豆腐干的五香麻辣卤汤液 |
| CN101421253A (zh) * | 2006-04-18 | 2009-04-29 | 阿斯利康(瑞典)有限公司 | 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物 |
| EP2013207B1 (en) | 2006-04-26 | 2012-04-25 | Cancer Research Technology Limited | Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
| EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
| US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| WO2008044688A1 (en) | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| EP2101819B1 (en) | 2006-11-20 | 2013-01-09 | President and Fellows of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
| EP2167692B1 (en) | 2007-07-10 | 2013-05-22 | Neurim Pharmaceuticals (1991) Ltd. | Cd44 splice variants in neurodegenerative diseases |
| EP2229391B1 (en) | 2007-12-19 | 2014-08-06 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2853897A1 (en) | 2008-05-08 | 2015-04-01 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| US8293748B2 (en) | 2008-10-02 | 2012-10-23 | Respivert Ltd. | p38 MAP kinase inhibitors |
| JP5670912B2 (ja) | 2008-12-11 | 2015-02-18 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| BR112012003926A2 (pt) | 2009-08-24 | 2020-08-11 | Genentech Inc | método para identificar um paciente não responsivo ao tratamento com um inibidor de b-raf, método para determinar se um tumor irá responder ao tratamento com um inibidor de b-raf, método para predizer se um paciente será não responsivo ao tratamento com um inibidor de braf específico, kit, método para classificar um tumor de mama, pulmão, cólon, ovário, tiroide, melanoma, ou pancreático e método para identificar um tumor não responsivo ao tratamento com um inibidor de b-raf |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| CA2786834C (en) | 2010-02-01 | 2018-10-16 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| WO2011124923A2 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | Novel compounds |
| WO2011124930A1 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | P38 map kinase inhibitors |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| US8933228B2 (en) | 2010-06-17 | 2015-01-13 | Respivert, Ltd. | Respiratory formulations and compounds for use therein |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| WO2012008564A1 (ja) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| WO2012149547A1 (en) | 2011-04-28 | 2012-11-01 | Duke University | Methods of treating hemoglobinopathies |
| JP2014523880A (ja) | 2011-06-23 | 2014-09-18 | ヴィアメット ファーマスーティカルズ，インコーポレイテッド | 金属酵素化合物 |
| WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
| SG2014005029A (en) | 2011-09-01 | 2014-03-28 | Novartis Ag | Use of organic compound for the treatment of noonan syndrome |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| PH12014500547A1 (en) | 2011-10-03 | 2014-04-21 | Respivert Ltd | 1-pyrazolyl-3-(-4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| WO2014033449A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| ES2856902T3 (es) | 2013-04-02 | 2021-09-28 | Oxular Acquisitions Ltd | Derivados de urea útiles como inhibidores de quinasa |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN113717162A (zh) | 2013-12-20 | 2021-11-30 | 奥苏拉收购有限公司 | 用作激酶抑制剂的脲衍生物 |
| JP6586098B2 (ja) | 2014-02-14 | 2019-10-02 | レスピバート・リミテツド | キナーゼ阻害剤としてのピラゾリル尿素 |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| US20170209445A1 (en) | 2014-10-01 | 2017-07-27 | Respivert Limited | Kinase inhibitors |
-
2008
- 2008-12-19 EP EP08862089.3A patent/EP2229391B1/en active Active
- 2008-12-19 MX MX2010006739A patent/MX2010006739A/es active IP Right Grant
- 2008-12-19 WO PCT/GB2008/004208 patent/WO2009077766A1/en not_active Ceased
- 2008-12-19 AU AU2008337286A patent/AU2008337286B2/en not_active Ceased
- 2008-12-19 UA UAA201008265A patent/UA105763C2/uk unknown
- 2008-12-19 BR BRPI0821227-9A patent/BRPI0821227A2/pt not_active Application Discontinuation
- 2008-12-19 DK DK08862089.3T patent/DK2229391T3/da active
- 2008-12-19 PL PL08862089T patent/PL2229391T3/pl unknown
- 2008-12-19 EA EA201070667A patent/EA019974B1/ru not_active IP Right Cessation
- 2008-12-19 CN CN200880126717.3A patent/CN101945869B/zh not_active Expired - Fee Related
- 2008-12-19 US US12/808,249 patent/US8198279B2/en not_active Expired - Fee Related
- 2008-12-19 CA CA2709257A patent/CA2709257C/en not_active Expired - Fee Related
- 2008-12-19 NZ NZ586418A patent/NZ586418A/xx unknown
- 2008-12-19 JP JP2010538900A patent/JP5511680B2/ja active Active
- 2008-12-19 ES ES08862089.3T patent/ES2520940T3/es active Active
- 2008-12-19 KR KR1020107015083A patent/KR101665143B1/ko not_active Expired - Fee Related
-
2010
- 2010-06-13 IL IL206330A patent/IL206330A/en active IP Right Grant
- 2010-06-25 ZA ZA2010/04524A patent/ZA201004524B/en unknown
-
2012
- 2012-04-28 US US13/459,120 patent/US8546387B2/en not_active Expired - Fee Related
-
2013
- 2013-09-24 US US14/035,133 patent/US8912191B2/en not_active Expired - Fee Related
-
2014
- 2014-11-17 US US14/543,379 patent/US9155737B2/en not_active Expired - Fee Related
-
2015
- 2015-09-14 US US14/853,199 patent/US9540372B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506591A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2020506178A5 (enExample) | ||
| DE60005850T2 (de) | Imidazo[1,2-a]pyridin- und pyrazolo[2,3-a]pyridinderivate | |
| JP2009534457A5 (enExample) | ||
| JP2004511462A5 (enExample) | ||
| JP2020505376A5 (enExample) | ||
| JP2019501223A5 (enExample) | ||
| JP2001510843A5 (enExample) | ||
| JP2019500315A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2014520898A5 (enExample) | ||
| WO2010042684A4 (en) | Pyrrolotriazine kinase inhibitors | |
| JP2010536887A5 (enExample) | ||
| JP2002543185A5 (enExample) | ||
| JP2005519908A5 (enExample) | ||
| JP2014503525A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2020520957A5 (enExample) | ||
| JP2011518819A5 (enExample) | ||
| JP2006519852A5 (enExample) | ||
| JP2011505356A5 (enExample) | ||
| JP2014530243A (ja) | Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物 | |
| JPH10287651A5 (enExample) | ||
| JP2018525430A5 (enExample) |